The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy.
about
Advances and hurdles on the way toward a leprosy vaccine.The continuing challenges of leprosyZanvil Alexander Cohn 1926-1993The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy.The cell wall mediates pneumococcal attachment to and cytopathology in human endothelial cells.Ontogeny and expansion of human natural killer cells: clinical implications.Rational immunotherapy with interleukin 2.Use of cytokines in infection.Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patientsNovel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healingZinc and infection: a review.Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches.Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.Leprosy therapy, past and present: can we hope to eliminate it?Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.Cytokine gene expression by cultures of human lymphocytes with autologous Mycobacterium tuberculosis-infected monocytesRecognition and destruction of Bacillus Calmette-Guerin-infected human monocytes.Stress-induced enhancement of cell-mediated immunity.
P2860
Q22305432-830CECB8-A79B-481E-BDA9-87D9722712A6Q24545809-388FEE64-226B-4FB0-B92A-DAC210117912Q24680249-9C99D2B8-4BF6-4268-9747-54F72B21D756Q30238551-559802A5-039E-41AB-838E-18CE836E1104Q33621043-ABA73760-186F-4CAF-8093-60455F610126Q34552167-CBFA37B8-8E6B-4DA5-A35C-68F5E586DC04Q35300674-BD882245-0B22-4995-8DE4-412A4A0264DBQ35967372-D8909DCD-5FD9-40C2-8C72-20EEC656064BQ36231351-794C39D1-9D9A-4279-A481-233BFA2D5BFFQ36231441-0B2AABCE-D85F-47F8-96BF-B717EEFEF96EQ36255320-B2043340-DD49-48BA-ADC7-5A41C2C8DC31Q36361254-E3437EEA-A6CD-4BF2-BAC9-C91A40355F12Q36839739-25A64066-D0AF-4450-BCBE-659D5834F470Q37451046-755E1017-A5CA-4DD7-92D5-592025EF45E6Q37856731-5F28D15A-8F07-4E2D-8091-14BA76FA9A15Q38883295-14E1651C-017C-4B63-B05B-3F5A453D190CQ39859774-22625BE2-2C9D-4CBA-B456-ABA3276A090FQ42941770-C42F341E-ED98-4F9F-958B-899EE65CE75AQ54134813-DA1DD91F-DC5D-4581-AB48-7863D61EFAED
P2860
The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
The systemic influence of reco ...... ations of lepromatous leprosy.
@ast
The systemic influence of reco ...... ations of lepromatous leprosy.
@en
type
label
The systemic influence of reco ...... ations of lepromatous leprosy.
@ast
The systemic influence of reco ...... ations of lepromatous leprosy.
@en
prefLabel
The systemic influence of reco ...... ations of lepromatous leprosy.
@ast
The systemic influence of reco ...... ations of lepromatous leprosy.
@en
P2093
P2860
P356
P1476
The systemic influence of reco ...... ations of lepromatous leprosy.
@en
P2093
G E Hancock
R Burkhardt
W J Britton
W J Theuvenet
P2860
P304
P356
10.1084/JEM.173.4.993
P407
P577
1991-04-01T00:00:00Z